Ocumension Therapeutics provided a TSR of 31% over the last twelve months. But that return falls short of the market. On the bright side, that's still a gain, and it is certainly better than the yearly loss of about 12% endured over half a decade. It could well be that the business is stabilizing. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Ocumension Therapeutics is showing 3 warning signs in our investment analysis, you should know about...